In vivo reprogramming drives Kras-induced cancer development

In vivo reprogramming drives Kras-induced cancer development

Cellular reprogramming and cancer development share properties. Here, the authors examine the impact of in vivo reprogramming on Kras-induced cancer and show reprogramming-mediated repression of somatic cell enhancers in conjunction with Kras mutation results in rapid PDAC development.

Bibliographic Details
Main Authors:	Hirofumi Shibata, Shingo Komura, Yosuke Yamada, Nao Sankoda, Akito Tanaka, Tomoyo Ukai, Mio Kabata, Satoko Sakurai, Bunya Kuze, Knut Woltjen, Hironori Haga, Yatsuji Ito, Yoshiya Kawaguchi, Takuya Yamamoto, Yasuhiro Yamada
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-018-04449-5

Similar Items

Epithelial expression of Gata4 and Sox2 regulates specification of the squamous–columnar junction via MAPK/ERK signaling in mice
by: Nao Sankoda, et al.
Published: (2021-01-01)

De Novo DNA Methylation at Imprinted Loci during Reprogramming into Naive and Primed Pluripotency
by: Masaki Yagi, et al.
Published: (2019-05-01)

DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency
by: Jumpei Taguchi, et al.
Published: (2021-08-01)

Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas
by: Shingo Komura, et al.
Published: (2019-09-01)

An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development
by: Shingo Komura, et al.
Published: (2016-04-01)

Identification of distinct loci for de novo DNA methylation by DNMT3A and DNMT3B during mammalian development
by: Masaki Yagi, et al.
Published: (2020-06-01)

The Long-Term Efficacy of Cochlear Implantation for Hearing Loss in Muckel-Wells Syndrome
by: Bakushi Ogawa, et al.
Published: (2019-12-01)

Epithelial expressions of Gata4 and Sox2 regulate specification of the squamous-columnar junction via MAPK/ERK signaling in mice
by: Sankoda, Nao
Published: (2021)

Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor
by: Yukinori Terada, et al.
Published: (2019-03-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)

Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs
by: Takashi Ikeda, et al.
Published: (2018-04-01)

A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor
by: Asahi Sato, et al.
Published: (2017-07-01)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2020-05-01)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
by: Masayuki Hiraki, et al.
Published: (2015-01-01)

Simplified structural map of Kras Kras (Slovene), Carso (Italian) = Geographical unit
by: Ladislav Placer
Published: (2015-07-01)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
by: Nicolas Bery, et al.
Published: (2020-06-01)

Synergistic gene editing in human iPS cells via cell cycle and DNA repair modulation
by: Thomas L. Maurissen, et al.
Published: (2020-06-01)

Diffusion tensor imaging of the optic chiasm in patients with intra- or parasellar tumor using readout-segmented echo-planar
by: Yamada, Hirofumi
Published: (2016)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
by: Jieqiong Wang, et al.
Published: (2016-05-01)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
by: Elisa Baldelli, et al.
Published: (2021-09-01)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
by: Alice Indini, et al.
Published: (2021-05-01)

Topographic effects on frequency-size distribution of landslides triggered by the Hokkaido Eastern Iburi Earthquake in 2018
by: Mio Kasai, et al.
Published: (2019-08-01)

Dry wall Kras 2011
by: Domen Zupančič
Published: (2012-01-01)

Clinical Significance of the KRAS Mutation
by: Sead Beganovic
Published: (2010-10-01)

Oncogenic KRAS Expression and Signaling
by: Lampson, Benjamin Logan
Published: (2012)

N-Terminal Amino Acids Determine KLF4 Protein Stability in 2A Peptide-Linked Polycistronic Reprogramming Constructs
by: Anika Reinhardt, et al.
Published: (2020-03-01)

Periportal Edema and Necrosis as Diagnostic Histological Features of Early Humoral Rejection in ABO-Incompatible Liver Transplantation
by: Haga, Hironori
Published: (2011)

Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations
by: Satoshi Inoue, et al.
Published: (2019-12-01)

Biphenotypic siononasal sarcoma with acute exacerbation: A case report
by: Hiroshi Okuda, et al.
Published: (2020-09-01)

KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice
by: Jasmine C. Wong, et al.
Published: (2020-11-01)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Xiufeng Pang, et al.
Published: (2016-10-01)

Targeting the untargetable KRAS in cancer therapy
by: Pingyu Liu, et al.
Published: (2019-09-01)

Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01)

KRAS mutation in biliary tract cholangiocarcinoma
by: Sora Yasri
Published: (2017-03-01)

Mutations in the KRAS gene in ovarian tumors.
by: Wiesława Niklińska, et al.
Published: (2009-12-01)

Clinical Relevance of KRAS in Human Cancers
by: Sylwia Jančík, et al.
Published: (2010-01-01)

Cellular fitness in response to oncogenic Kras
by: Caldwell, M. E.
Published: (2011)

Teknologi penyamakan kulit kras buaya
by: Bambang Oetojo, et al.
Published: (1992-08-01)

Kras: trajnostni razvoj kraške pokrajine
Published: (2008)

An integrated model for predicting KRAS dependency
by: Chareddy, Y.S, et al.
Published: (2023)